Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 14

765P - Comprehensive analysis of the association between RAS mutation and immune checkpoint marker expression

Date

10 Sep 2022

Session

Poster session 14

Topics

Tumour Immunology;  Translational Research

Tumour Site

Presenters

Hirotakka Miyashita

Citation

Annals of Oncology (2022) 33 (suppl_7): S331-S355. 10.1016/annonc/annonc1058

Authors

H. Miyashita1, R. Kurzrock2, S. Lee3, S. Pabla4, M. Nesline4, S. Glenn4, J. Conroy4, P. DePietro4, S. Kato3

Author affiliations

  • 1 Internal Medicine, Mount Sinai Beth Israel, 10003 - New York/US
  • 2 Medicine, Medical College of Wisconsin, Milwaukee/US
  • 3 Center For Personalized Cancer Therapy, University of California San Diego - UCSD, 92093 - La Jolla/US
  • 4 Clinical Evidence Development, OmniSeq Inc., 14203 - Buffalo/US
More

Abstract 765P

Background

The effectiveness of KRAS G12C inhibition as a cancer treatment was recently reported. Knowing the association between RAS mutation and the expression level of immune checkpoint markers is of interest since it may guide a potential combination therapy of RAS inhibition and immune checkpoint blockade.

Methods

498 patients with various types of solid tumors were included in the analysis. The RNA expression levels of immune checkpoint markers in these patients’ samples were measured by RNA sequencing, normalized by internal housekeeping gene profiles, and ranked from 0 to 100th percentile against a pan-cancer reference population of 735 tumors. “High” expression was defined as expression rank ≥75th percentile. Genomic variants in the tumor samples and/or serum cell-free DNA (cfDNA) were analyzed with next-generation sequencing and the mutational status of the RAS gene family (KRAS, NRAS, and HRAS) were summarized.

Results

The most common types of cancer in the cohort were colorectal and pancreatic cancer. (27.7% and 10.8%, respectively). 163 patients (32.7%) harbored RAS mutation or amplification in the tumor or serum cfDNA. The most common RAS mutations were KRAS G12D and G12V. (27.6% and 19.0%, respectively) RAS-mutant patients had a significantly larger proportion of high NOS2 expression compared to RAS-wild type patients (35.0% vs 17.0%, p < 0.001). In contrast, RAS-wild type patients had a significantly larger proportion of VTCN1 (B7-H4) high expression compared to RAS-mutant patients. (23.3% vs 8.0%, p < 0.001). After adjusting for tumor type, sex, and age, a significant inverse association between high VTCN1 expression and RAS-mutant status was seen (p = 0.012). No other checkpoint markers including PD-1, PD-L1, CTLA4 or LAG3, showed significant association with RAS status.

Conclusions

Patients with RAS mutations are less likely to have high expression of VTCN1. VTCN1 is a co-inhibitory molecule which negatively regulates T-cell immune response and promotes immune escape. The association between genetic mutations in cancer cells and the immune status in the tumor microenvironment may suggest potential treatment with combination targeted therapy plus immunotherapy.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

This study was funded in part by the Joan and Irwin Jacobs Fund and NIH P30 CA023100.

Disclosure

R. Kurzrock: Financial Interests, Invited Speaker: Biological Dynamics, Boehringer Ingelheim, Debiopharm, Foundation Medicine, Genentech, Grifols, Guardant, Incyte, Konica Minolta, Medimmune, Merck Serono, Omniseq, Pfizer, Sequenom, Takeda, TopAlliance, Actuate Therapeutics, AstraZeneca, Bicara Therapeutics, Biological Dynamics, Eisai, EOM Pharmaceuticals, Iylon, Merck, NeoGenomics, Neomed, Pfizer, Prosperdtx, Roche, TD2/Volastra, Turning Point Therapeutics, X-Biotech, CureMatch Inc, CureMetrix, IDbyDNA. S. Pabla: Financial Interests, Stocks/Shares: Omniseq. M. Nesline: Financial Interests, Stocks/Shares: Omniseq. S. Glenn: Financial Interests, Stocks/Shares: Omniseq. J. Conroy: Financial Interests, Stocks/Shares: Omniseq. P. DePietro: Financial Interests, Stocks/Shares: Omniseq. S. Kato: Financial Interests, Invited Speaker: Foundation Medicine, NeoGenomics, CureMatch, Roche, Pfizer, ACT Genomics, Sysmex, Konica Minolta, OmniSeq. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.